Pediatrix Medical Group, Inc. - 10-Q Summary (Period Ended June 30, 2003)
Business Context and Reporting Period
This Quarterly Report on Form 10-Q covers the three and six-month periods ended June 30, 2003. Pediatrix Medical Group, Inc. operates as a physician group practice specializing in neonatal and perinatal care, as well as newborn screening services. The company continues to pursue growth through acquisitions and organic volume expansion.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended June 30, 2003 | Six Months Ended June 30, 2003 |
|---|---|---|
| Net Patient Service Revenue | $133,701 | $259,901 |
| Income from Operations | $32,426 | $59,994 |
| Net Income | $19,885 | $36,884 |
| Diluted EPS | $0.82 | $1.49 |
| Operating Margin | 24.3% | 23.1% |
| Cash and Cash Equivalents (End of Period) | $11,554 | $11,554 |
| Line of Credit Outstanding | $17,000 | $17,000 |
| Working Capital | $32,177 | $32,177 |
Note: Working capital calculated as Total Current Assets ($107,822) minus Total Current Liabilities ($75,645).
Material Changes vs. Prior Period
- Revenue Growth: Net patient service revenue increased 15.0% ($17.5 million) for the quarter and 16.3% ($36.4 million) for the six months compared to the prior year. Approximately 28% of the quarterly increase was attributable to acquisitions.
- Profitability: Net income rose 17.2% for the quarter and 21.2% for the six months. Operating margins improved slightly to 24.3% (quarter) and 23.1% (six months), driven by a reduction in general and administrative expenses as a percentage of revenue.
- Liquidity: Cash and cash equivalents decreased significantly from $73.2 million at December 31, 2002, to $11.6 million at June 30, 2003. This reduction was primarily due to $46.2 million in acquisition payments and $74.8 million in treasury stock repurchases.
- Debt: The company utilized its line of credit, with an outstanding balance of $17.0 million at June 30, 2003, compared to zero at the end of 2002.
Guidance, Outlook, Risks, and Unusual Items
- Acquisitions: The company completed the acquisition of a newborn metabolic screening laboratory and two physician group practices for approximately $46.0 million in cash during the first six months of 2003. Subsequent to the period end, two additional practices were acquired for $7.3 million.
- Stock Repurchases: The company completed a $50 million repurchase program in Q1 and initiated a new $50 million program in April 2003. Approximately 730,000 shares were repurchased in Q2 for $24.8 million.
- Legal and Regulatory Risks:
- Securities Litigation: Several class-action lawsuits were filed in June and July 2003 alleging violations of antifraud provisions related to billing practices and results of operations.
- Government Investigations: The company is under investigation by a U.S. Attorney's Office regarding Medicaid billing practices nationwide. Additionally, the Federal Trade Commission (FTC) is investigating competition issues related to the 2001 acquisition of Magella Healthcare Corporation.
- TRICARE Investigation: An ongoing federal investigation regarding billing practices for military dependents remains active.
- Accounting Policies: The company uses the intrinsic value method for stock-based compensation. Pro forma net income would be lower if fair value accounting (FAS 123) were applied.
Investor Verification Checklist
- Verify the status and potential financial impact of the ongoing U.S. Attorney's Office investigation into Medicaid billing practices.
- Monitor the progress of the FTC investigation regarding the Magella Healthcare acquisition and competition issues.
- Assess the integration and revenue contribution of the recent acquisitions (laboratory and physician groups) against the $46 million cash outlay.
- Review the company's cash burn rate given the significant reduction in cash reserves and the utilization of the $100 million line of credit.
- Confirm the outcome of the pending securities class-action lawsuits filed in mid-2003.